5/26/2010

Theratechnologies' tesamorelin reduced excess abdominal fat by an average of 17.5% but appeared to increase the risk of diabetes in HIV patients, FDA staff said. The agency's report was issued ahead of a panel review of the drug Thursday.

Related Summaries